9 Meters Biopharma Inc

NASDAQ:NMTR   3:45:57 PM EDT
1.09
-0.01 (-0.91%)
Regulatory, Other Pre-Announcement

9 Meters Biopharma Reports Q3 Loss Per Share $0.06

Published: 11/09/2020 14:52 GMT
9 Meters Biopharma Inc (NMTR) - Q3 Loss per Share $0.06.
Phase 1b/2a Trial With a Proprietary Long-acting Glp-1 Agonist in Short Bowel Syndrome Top-line Data Expected in Q4.
Continued Enrollment of Phase 3 Trial With Larazotide in Celiac Disease, Interim Analysis Remains on Target for 1h 2021.
As of Sept 30, 2020, Co's Cash and Cash Equivalents Totaled About $12.4 Million.
Q3 Earnings per Share View $-0.06 -- Refinitiv Ibes Data (analyst estimates).